Brukinsa (Zanubrutinib) is a kinase inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Dosage: The recommended zanubrutinib dose is 160mg administered by mouth twice a day or 320mg administered by mouth once daily until the disease is progressive or unacceptable toxicity occurs. Zanubrutinib can be taken with or without food. Patients are advised to swallow capsules whole with water, without being opened, broken, or chewed. If a dose of zanubrutinib is forgotten or missed, it should be administered promptly on the same day with a return to the normal schedule the following day.
Side Effects: The most commonly reported zanubrutinib side effect include:
- Neutrophil count decreased
- Platelet count decreased
- Upper respiratory tract infection
- White blood cell count decreased
- Hemoglobin decreased
Warnings and Precautions:
- Monitor patients with zanubrutinib 80 mg for signs/symptoms of bleeding. Discontinue therapy in occurrence of intracranial hemorrhage of any grade.
- Monitor and evaluate patients with zanubrutinib for fever or other signs and symptoms of infection and treat promptly.
- Monitor patients with zanubrutinib 80 mg for complete blood counts during therapy and treat using growth factor or transfusions, as required.
- Patients with the therapy of brukinsa should be monitored for signs or symptoms of atrial fibrillation and atrial flutter and should be managed as appropriate.
- Pregnancy testing is recommended for females of reproductive age prior to starting brukinsa 80 mg therapy. Women are advised to avoid becoming pregnant while on the therapy with brukinsa and for at least 7 days after the last dose.
- Men are advised to avoid fathering a child while on Brukinsa therapy and for at least 7 days following the last dose.
- Due to the potential for serious side effects from brukinsa 80 mg in a breastfed child, lactating women are advised not to breastfeed while on therapy and for at least 14 days after the last dose.